{
  "id": "resp_0a12fef3b4eef79300693c8aaad66481939acf0d743b50521b",
  "object": "response",
  "created_at": 1765575338,
  "status": "completed",
  "background": false,
  "billing": {
    "payer": "developer"
  },
  "error": null,
  "incomplete_details": null,
  "instructions": null,
  "max_output_tokens": null,
  "max_tool_calls": null,
  "model": "gpt-5.2-2025-12-11",
  "output": [
    {
      "id": "rs_0a12fef3b4eef79300693c8aabe1148193968551c9f04cdc71",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0a12fef3b4eef79300693c8aad2d64819385f00452b9be7071",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "CDK12/13 inhibitor TNBC China trial NCT"
      }
    },
    {
      "id": "rs_0a12fef3b4eef79300693c8aafd6ec8193b38b56ea6063d3bc",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0a12fef3b4eef79300693c8ab339048193aad0cd7949aa982e",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "China CDK12 inhibitor clinical trial"
      }
    },
    {
      "id": "rs_0a12fef3b4eef79300693c8ab4efec81938d19a50bc09391a7",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0a12fef3b4eef79300693c8ab9dad481938d0e55e84bd540e8",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "site:clinicaltrials.gov CDK12 breast cancer"
      }
    },
    {
      "id": "rs_0a12fef3b4eef79300693c8abbd3a48193acaf4b2ad379f5ae",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0a12fef3b4eef79300693c8abe331881939c6ccb915f6ca424",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "open_page",
        "url": "https://synapse.zhihuiya.com/drug/8fb030514b004a0eb2b730b10ce2bbd0"
      }
    },
    {
      "id": "rs_0a12fef3b4eef79300693c8abf7ce881938a31987ecfaba4e3",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0a12fef3b4eef79300693c8ac5324081938185f87b7d6735e9",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "CT7439 China site"
      }
    },
    {
      "id": "rs_0a12fef3b4eef79300693c8ac7a5708193937aca52bb869977",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0a12fef3b4eef79300693c8acda7848193bda656bf2ea94604",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "\"CDK12\" inhibitor \"China\" \"phase 1\""
      }
    },
    {
      "id": "rs_0a12fef3b4eef79300693c8ad195ac81939070095e1aaf6cc5",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0a12fef3b4eef79300693c8ad8093c8193869c659742d2b350",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "ISM9274 IND China NMPA"
      }
    },
    {
      "id": "rs_0a12fef3b4eef79300693c8adc6d5c81938d02205f680083e7",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0a12fef3b4eef79300693c8adff488819392180b42aeb46d43",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "open_page",
        "url": "https://www.globenewswire.com/news-release/2024/09/23/2951333/0/en/Carrick-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-CT7439-CDK12-13-Inhibitor.html"
      }
    },
    {
      "id": "rs_0a12fef3b4eef79300693c8ae2c8b88193a57a2bedbac72e1f",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0a12fef3b4eef79300693c8ae2faac81938d831500b2ef1aa3",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "find_in_page",
        "pattern": "CT7439",
        "url": "https://www.carricktherapeutics.com/pipeline/cdk1213-inhibitor"
      }
    },
    {
      "id": "rs_0a12fef3b4eef79300693c8ae5fb6c8193839d35fc0baa57b8",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0a12fef3b4eef79300693c8ae969e48193b9d0b3ffadcd1343",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "open_page",
        "url": "https://www.carricktherapeutics.com/pipeline/cdk1213-inhibitor"
      }
    },
    {
      "id": "rs_0a12fef3b4eef79300693c8aed0b0081939c39d1ed7355e8d7",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0a12fef3b4eef79300693c8aedc03081938513177be3965d99",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "find_in_page",
        "pattern": "CT7439",
        "url": "https://breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-025-02101-x"
      }
    },
    {
      "id": "rs_0a12fef3b4eef79300693c8af0dd0881939d17378115b3da74",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0a12fef3b4eef79300693c8af1bcc0819399237d88309db5d2",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "open_page",
        "url": "https://link.springer.com/article/10.1186/s13058-025-02101-x"
      }
    },
    {
      "id": "rs_0a12fef3b4eef79300693c8af33c1c8193be2fe2b257a0abaa",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0a12fef3b4eef79300693c8af39f48819384ebc8f4ba310cfb",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "find_in_page",
        "pattern": "CT7439",
        "url": "https://link.springer.com/article/10.1186/s13058-025-02101-x"
      }
    },
    {
      "id": "rs_0a12fef3b4eef79300693c8af61edc8193b011020a9b677545",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0a12fef3b4eef79300693c8afaa7a48193b6e13ddc8d4979e8",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "open_page",
        "url": "https://insilico.com/pipeline_target_cdk12/13"
      }
    },
    {
      "id": "rs_0a12fef3b4eef79300693c8afd5bfc8193a0bbe0c3ef85f85c",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "msg_0a12fef3b4eef79300693c8b141f9c81938f887b134b29974d",
      "type": "message",
      "status": "completed",
      "content": [
        {
          "type": "output_text",
          "annotations": [
            {
              "type": "url_citation",
              "end_index": 852,
              "start_index": 652,
              "title": "Carrick Therapeutics Announces First Patient Dosed in Phase",
              "url": "https://www.globenewswire.com/news-release/2024/09/23/2951333/0/en/Carrick-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-CT7439-CDK12-13-Inhibitor.html"
            },
            {
              "type": "url_citation",
              "end_index": 1373,
              "start_index": 1282,
              "title": "CDK12/13 Inhibitor :: Carrick Therapeutics, Inc.",
              "url": "https://www.carricktherapeutics.com/pipeline/cdk1213-inhibitor"
            },
            {
              "type": "url_citation",
              "end_index": 1742,
              "start_index": 1650,
              "title": "CT-7439(CT-7439) - 药物靶点：CCNK x CDK12 x CDK13_在研适应症：恶性实体肿瘤，肿瘤，乳腺癌_专利_临床_研发",
              "url": "https://synapse.zhihuiya.com/drug/8fb030514b004a0eb2b730b10ce2bbd0"
            },
            {
              "type": "url_citation",
              "end_index": 2246,
              "start_index": 2176,
              "title": "Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer - PubMed",
              "url": "https://pubmed.ncbi.nlm.nih.gov/31668947/"
            },
            {
              "type": "url_citation",
              "end_index": 2722,
              "start_index": 2652,
              "title": "Noncovalent CDK12/13 dual inhibitors-based PROTACs degrade CDK12-Cyclin K complex and induce synthetic lethality with PARP inhibitor - PubMed",
              "url": "https://pubmed.ncbi.nlm.nih.gov/34864331/"
            },
            {
              "type": "url_citation",
              "end_index": 3193,
              "start_index": 3125,
              "title": "Insilico Medicine nominates novel CDK12/13 small molecule inhibitor as preclinical candidate for multiple tumors | EurekAlert!",
              "url": "https://www.eurekalert.org/news-releases/1004993"
            },
            {
              "type": "url_citation",
              "end_index": 3731,
              "start_index": 3668,
              "title": "CDK12/13 | Insilico Medicine",
              "url": "https://insilico.com/pipeline_target_cdk12/13"
            },
            {
              "type": "url_citation",
              "end_index": 4153,
              "start_index": 4100,
              "title": "YJ1206 | CAS#3053716-98-3 | CDK12/CDK13 PROTAC degrader | MedKoo",
              "url": "https://www.medkoo.com/products/60512"
            },
            {
              "type": "url_citation",
              "end_index": 4509,
              "start_index": 4436,
              "title": "US11666578B2 - Small molecule inhibitors of CDK12/CDK13 \n        - Google Patents",
              "url": "https://patents.google.com/patent/US11666578B2/en"
            }
          ],
          "logprobs": [],
          "text": "- **Carrick Therapeutics — “Carrick Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT7439 (CDK12/13 Inhibitor)”**  \n  **URL:** `https://www.globenewswire.com/news-release/2024/09/23/2951333/0/en/Carrick-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-CT7439-CDK12-13-Inhibitor.html`  \n  **Direct quote snippets:**  \n  - “CT7439, a novel cyclin dependent kinase 12/13 (CDK12/13) inhibitor / Cyclin-K glue-degrader.”  \n  - “Clinical trial details can also be found on www.clinicaltrials.gov under study ID: NCT06600789.”  \n  - “CT7439 is an inhibitor of CDK12/13 as well as a 'glue degrader' of Cyclin-K” ([globenewswire.com](https://www.globenewswire.com/news-release/2024/09/23/2951333/0/en/Carrick-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-CT7439-CDK12-13-Inhibitor.html))\n\n- **Carrick Therapeutics — “CDK12/13 Inhibitor” (pipeline page)**  \n  **URL:** `https://www.carricktherapeutics.com/pipeline/cdk1213-inhibitor`  \n  **Direct quote snippets:**  \n  - “CT7439: CDK12/13 inhibitor/Cyclin-K Degrader”  \n  - “CT7439 is a CDK12/13/Cyclin-K degrader, which potently inhibits the cellular activity of CDK12/13.”  \n  - “The compound acts as an inhibitor of CDK12 but also as a 'glue degrader' of Cyclin-K” ([carricktherapeutics.com](https://www.carricktherapeutics.com/pipeline/cdk1213-inhibitor))\n\n- **智慧芽 Synapse — “CT-7439 (CT-7439)” (drug/pipeline entry)**  \n  **URL:** `https://synapse.zhihuiya.com/drug/8fb030514b004a0eb2b730b10ce2bbd0`  \n  **Direct quote snippets:**  \n  - “别名 CT-7439、CT7439”  \n  - “靶点 【CCNK x CDK12 x CDK13】”  \n  - “NCT06600789 / Recruiting 临床1/2期” ([synapse.zhihuiya.com](https://synapse.zhihuiya.com/drug/8fb030514b004a0eb2b730b10ce2bbd0))\n\n- **PubMed — “Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer”**  \n  **URL:** `https://pubmed.ncbi.nlm.nih.gov/31668947/`  \n  **Direct quote snippets:**  \n  - “SR-4835, a highly selective dual inhibitor of CDK12 and CDK13, which disables triple-negative breast cancer (TNBC) cells.”  \n  - “Keywords:  BRCAness; CDK12; CDK13; PARP inhibitor; cisplatin; intronic polyadenylation; triple-negative breast cancer.” ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/31668947/))\n\n- **PubMed — “Noncovalent CDK12/13 dual inhibitors-based PROTACs…”**  \n  **URL:** `https://pubmed.ncbi.nlm.nih.gov/34864331/`  \n  **Direct quote snippets:**  \n  - “we have synthesized a potent PROTAC degrader PP-C8 based on the noncovalent dual inhibitors of CDK12/13”  \n  - “PP-C8 demonstrates profound synergistic antiproliferative effects with PARP inhibitor in triple-negative breast cancer (TNBC).” ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/34864331/))\n\n- **EurekAlert! — “Insilico Medicine nominates novel CDK12/13 small molecule inhibitor…”**  \n  **URL:** `https://www.eurekalert.org/news-releases/1004993`  \n  **Direct quote snippets:**  \n  - “ISM9274 is a highly selective covalent inhibitor of CDK12/13.”  \n  - “particularly in triple-negative breast cancer, pancreatic cancer”  \n  - “ISM9274, a highly selective covalent dual-inhibitor of CDK12/13” ([eurekalert.org](https://www.eurekalert.org/news-releases/1004993))\n\n- **Insilico Medicine — “CDK12/13 (CDK12/13) Inhibitor: Treating Tumors through Induction of BRCAness (IND-Enabling)”**  \n  **URL:** `https://insilico.com/pipeline_target_cdk12/13`  \n  **Direct quote snippets:**  \n  - “Cyclin-dependent kinase 12/13 (CDK12/13) Inhibitor: Treating Tumors through Induction of BRCAness (IND-Enabling)”  \n  - “Potent anti-proliferation activity in BRCAm and beyond BRCAm TNBC tumors”  \n  - “Indications * Triple negative breast cancer (TNBC)” ([insilico.com](https://insilico.com/pipeline_target_cdk12/13))\n\n- **MedKoo — “YJ1206 | CAS#3053716-98-3 | CDK12/CDK13 PROTAC degrader”**  \n  **URL:** `https://www.medkoo.com/products/60512`  \n  **Direct quote snippets:**  \n  - “MedKoo Cat#: 128339  | Name:  YJ1206”  \n  - “YJ1206 is a proteolysis-targeting chimera (PROTAC) engineered to selectively degrade cyclin-dependent kinases 12 and 13 (CDK12/13).”  \n  - “CAS#3053716-98-3” ([medkoo.com](https://www.medkoo.com/products/60512))\n\n- **Google Patents — “US11666578B2 - Small molecule inhibitors of CDK12/CDK13”**  \n  **URL:** `https://patents.google.com/patent/US11666578B2/en`  \n  **Direct quote snippets:**  \n  - “US11666578B2 - Small molecule inhibitors of CDK12/CDK13”  \n  - “Publication number US11666578B2” ([patents.google.com](https://patents.google.com/patent/US11666578B2/en))"
        }
      ],
      "role": "assistant"
    }
  ],
  "parallel_tool_calls": true,
  "previous_response_id": null,
  "prompt_cache_key": null,
  "prompt_cache_retention": null,
  "reasoning": {
    "effort": "medium",
    "summary": null
  },
  "safety_identifier": null,
  "service_tier": "default",
  "store": true,
  "temperature": 1.0,
  "text": {
    "format": {
      "type": "text"
    },
    "verbosity": "medium"
  },
  "tool_choice": "auto",
  "tools": [
    {
      "type": "web_search",
      "filters": null,
      "search_context_size": "medium",
      "user_location": {
        "type": "approximate",
        "city": null,
        "country": "US",
        "region": null,
        "timezone": null
      }
    }
  ],
  "top_logprobs": 0,
  "top_p": 0.98,
  "truncation": "disabled",
  "usage": {
    "input_tokens": 63040,
    "input_tokens_details": {
      "cached_tokens": 4352
    },
    "output_tokens": 6280,
    "output_tokens_details": {
      "reasoning_tokens": 4927
    },
    "total_tokens": 69320
  },
  "user": null,
  "metadata": {}
}